Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pegylation: a novel process for modifying pharmacokinetics.

J M Harris1, N E Martin, M Modi

  • 1Shearwater Corporation, Huntsville, Alabama 35801, USA. jmharris@swpolymers.com

Clinical Pharmacokinetics
|August 21, 2001
PubMed
Summary

Polyethylene glycol (PEG) modification, or pegylation, enhances parenteral drug delivery by improving pharmacokinetics and reducing immunogenicity. Tailoring PEG properties is crucial for optimizing therapeutic efficacy on a protein-specific basis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High-resolution X-ray fluorescence imaging of silver-based contrast agents by EDXRF spectrometry: A preclinical study.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Monitoring and Modeling Population Exposures to Air Pollutants from Oil and Gas Development: Part 1. Predictive, Source-Oriented Modeling and Measurements to Evaluate Community Exposures to Air Pollutants and Noise from Unconventional Oil and Gas Development.

Research report (Health Effects Institute)·2026
Same author

Decompressive craniectomy to cranioplasty: a retrospective observational study using Hospital Episode Statistics in England.

BMJ surgery, interventions, & health technologies·2024
Same author

Comparative analysis of Truenat™ MTB Plus and Xpert<sup>®</sup> Ultra in diagnosing tuberculous meningitis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Improvements in beam's eye view fiducial tracking using a novel multilayer imager.

Physics in medicine and biology·2021
Same author

The reliability of pseudoneglect is task dependent.

Neuropsychologia·2020

Area of Science:

  • Biotechnology
  • Pharmaceutical Sciences
  • Drug Delivery Systems

Background:

  • Liposomal carriers and pegylation are common parenteral drug delivery enhancement strategies.
  • Classical liposomes have limitations despite improving clearance and passive targeting.
  • Pegylation modifies therapeutic proteins, impacting pharmacokinetics and pharmacodynamics.

Purpose of the Study:

  • To explore the benefits and mechanisms of pegylation in parenteral drug delivery.
  • To understand how pegylation affects drug clearance, absorption, distribution, and plasma concentrations.
  • To evaluate the impact of pegylation on drug efficacy, adverse effects, and immunogenicity.

Main Methods:

  • Review of existing literature on liposomal carriers and pegylation.

Related Experiment Videos

  • Analysis of pharmacokinetic and pharmacodynamic changes associated with pegylated therapeutic agents.
  • Examination of factors influencing pegylation efficacy, including PEG size, geometry, and attachment site.

    • Main Results:

    • Pegylation reduces renal clearance and can lead to sustained absorption and restricted distribution.
    • Modified pharmacokinetic profiles result in more constant plasma concentrations, enhancing efficacy for concentration-dependent effects.
    • Pegylation can decrease adverse effects and protein immunogenicity through steric hindrance.
    • Two PEG-modified proteins are FDA-approved; others, including pegylated interferon-alpha (IFNalpha), are in development.

    Conclusions:

    • Pegylation is an effective strategy for enhancing therapeutic protein delivery and optimizing pharmacokinetic/pharmacodynamic properties.
    • Careful design, considering PEG characteristics and protein-specific attributes, is essential for therapeutic optimization.
    • Pegylated agents offer potential advantages in sustained drug delivery, improved efficacy, and reduced adverse effects, particularly in areas like antiviral therapy.